Rezolute, Inc. is a rare disease company developing novel therapies intended to improve quality of life for patients and families. Its work focuses on hyperinsulinism, a condition that can cause dangerously low blood sugar. The company’s lead development program is ersodetug, a potential treatment for hypoglycemia associated with congenital and tumor hyperinsulinism. Rezolute reports two Phase 3 programs for these conditions and provides information about its clinical trials and development pipeline.

The company’s website offers resources for people affected by hyperinsulinism, including explanations of the condition and patient and family stories about its everyday challenges. It also shares therapeutic research, publications, presentations, and updates on investigator-initiated studies. For investors and the wider public, Rezolute provides corporate information, financial and stock resources, regulatory filings, press releases, and event updates. The organization also highlights its mission, leadership, and workplace culture, and invites people interested in its work to explore job openings. Rezolute’s activities center on developing potential treatments; the information provided does not indicate that ersodetug is an approved or marketed therapy.